Loberamisal for Acute Ischemic Stroke: The LAIS Randomized Clinical Trial.

Intravenous loberamisal in acute ischemic stroke patients treated within 48 hours increased 90-day full functional outcomes to 69.7% versus 56.3% with placebo.

• Why it matters: Neuroprotective and neuroreparative options for acute ischemic stroke are limited, leaving a need for effective, safe treatments that improve long-term function.
• What they did: In a multicenter, double-blind, randomized phase 3 trial in China (32 hospitals), adults with NIHSS 7–20 received 40 mg loberamisal or matching placebo once daily for 10 days plus standard care.
• The result: At 90 days, mRS 0–1 was higher with loberamisal (relative risk 1.24; 95% CI 1.12–1.36; risk difference 13.28%; 95% CI 7.24%–19.32%), with similar adverse-event rates and lower mortality (1.2% vs 2.0%).

AI summary of the abstract · may contain errors · not medical advice · read the paper.